Results 171 to 180 of about 6,861,462 (220)
Autism Research, EarlyView.ABSTRACT Many autistic individuals with average or higher cognitive abilities (also referred to as intelligence quotient; IQ) exhibit weaker than expected daily living skills (DLS). However, existing evidence is primarily cross‐sectional. This study examined: (1) how IQ‐DLS discrepancies develop from early childhood through early adulthood, (2) whether
Elaine B. Clarke +2 more
wiley +1 more source
Autism Research, EarlyView.ABSTRACT High levels of parental stress and psychological inflexibility are common among caregivers raising children with neurodevelopmental disabilities. Navigator ACT is a group‐based treatment developed to increase psychological flexibility and reduce the impact of stress among parents of children with various disabilities (e.g., autism spectrum ...
T. Holmberg Bergman +3 more
wiley +1 more source
Autism Research, EarlyView.ABSTRACT Irritability is a prevalent and impairing feature associated with autism, yet remains poorly understood, particularly in adults. Drawing heavily on insights translated from pediatric and transdiagnostic literatures, we propose that irritability in autistic individuals often reflects a psychophysiological stress or threat response, rooted in a ...
Hsiang‐Yuan Lin +3 more
wiley +1 more source
The Unique Roles of Executive Function in Co‐Occurring Psychopathologies in Autism
Autism Research, EarlyView.ABSTRACT Children with autism spectrum disorder (ASD) often experience co‐occurring psychiatric conditions, such as anxiety and attention‐deficit/hyperactivity disorder (ADHD), which significantly impair daily functioning. However, the underlying mechanisms linking these conditions to core ASD features remain poorly understood.
Shing‐Him Ng +13 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić +4 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Within the ConcePTION project we set out to design two mother–infant pair studies collecting breast milk and plasma from the mother and plasma from the infant (for metformin and prednisolone) in order to demonstrate the premises and conditions for investigating potential drug transfer in association with breastfeeding.
Mats Hansson +11 more
wiley +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
British Journal of Clinical Pharmacology, EarlyView.Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić +4 more
wiley +1 more source